TLV logotyp
TLV logotyp

Prognostic platforms in the field of breast cancer

TLV is currently working on several health economic evaluations of so-called tumor profiling tests to guide adjuvant chemotherapy decisions in early breast cancer.

The products under evaluation are the following:

  • Oncotype DX
  • MammaPrint
  • ProSigna

These health economic evaluations are carried out on the request of the Medical technology council (MTP-rådet), which is responsible for managed introduction of new medical devices.

Information about the order can also be found on the MTP-rådet’s website. You will find the link under related information to the right.

The health economic evaluations will be carried out in spring 2021.

Publicerad 12 februari 2021